# Senzer Limited (09458564)

> Why UK company 09458564 went into administration, from the administrators' statement filed at Companies House, by companydig. Interactive version: https://companydig.co.uk/company/09458564

- **Status:** Administration ended
- **Administration began:** 2021-01-11
- **Administrators:** Stephen Powell, Julie Anne Palmer
- **Administrators' firm:** Begbies Traynor
- **Incorporated:** 2015-02-25
- **Location:** Salisbury
- **Industry:** 32500 Manufacture of medical and dental instruments and supplies

## Why it went into administration

- COVID-19
- Funding withdrawn / unable to refinance
- Cash flow / liquidity pressure
- HMRC / tax arrears
- Creditor pressure / legal action

## From the administrators' statement

Senzer was incorporated in 2015 to develop and commercialise respiratory therapeutics in the field of cannabinoids. The Company in-licensed a portfolio of patents from Kind Consumer Ltd that has developed a miniaturised breath operated inhaler as a licensed medicine for nicotine delivery.

In late 2015, Senzer signed a commercial licensing agreement with former Nasdaq listed Insys Therapeutics to commercialise two inhaled cannabinoid products for chemotherapy nausea relief and pain relief for the US. Senzer was responsible for the development and manufacture of these products for clinical trials and for device commercialisation and scale up. In 2018 after successful development of the products and engagement with the FDA, a proof of concept Phase 1 study was carried out which demonstrated superior pharmacokinetics to the reference product, confirming the 505(b)2 route.

Senzer continued to develop its own portfolio for UK and Europe, which included gaining a class 2a CE mark in conjunction with its inhaler manufacturing partner Europlaz. In 2019 however, Insys Therapeutics filed for Chapter 11 in the USA and in January 2020, Senzer acquired the unencumbered rights to these FDA programmes. During 2020, the company broadened its portfolio by launching an unlicensed ‘special’ medicine through Twenty21, the UK’s first cannabis patient registry and dosing its first UK patient. Senzer also prepared a consumer CBD product to the point of commercialisation launch in the UK.

Statement of proposals: https://find-and-update.company-information.service.gov.uk/company/09458564/filing-history/MzI5MDk2NzYzMWFkaXF6a2N4/document?format=pdf&download=0
Companies House register: https://find-and-update.company-information.service.gov.uk/company/09458564

Contains public sector information from Companies House, licensed under the Open Government Licence v3.0.